Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Comment by
Whalewatcher1
on Dec 27, 2021 7:30pm
RE:Whalewatcher1 when you're going for the jugular don't miss!
Hi C10H12N2, maybe you understand this better. However I don't see how they qualify for the net income standard as they don't make any income and would need history of over $1M per year, see
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Dec 27, 2021 4:35pm
Whalewatcher1 when you're going for the jugular don't miss!
Whalewatcher, you need to understand Nasdaq is a 3 Tiered system. Algernon qualifies for an uplisting under "The Net Income Standard". Another big misunderstanding about uplisting is the
...more
Debt-Free and Thriving: Mining Company Reports 35% Revenue Growth in Q3 2024
posted Nov 12, 2024 9:00am by
Mandalay Resources Corp.
-
|
"Revenue growth and free cash flow generation reflect our cost controls and prudent capital management while benefitting from high metal prices. As of the end of Q3 our cash balance was a healthy $54.7 million – more than doubling since December 2023 – and we have fully repaid the $20 million outstanding balance on our revolving credit facility, strengthening our liquidity and financial flexibility ...read more
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Comment by
Whalewatcher1
on Dec 27, 2021 12:45pm
RE:RE:RE:RE:RE:RE:RE:Wednesday Trading
How does this stock get uplisted to Nasdaq? They will need major $ raise to meet minimum listing requiremts. Search for yourself the Nasdaq listing requirements including year plus cash based on
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Dec 24, 2021 9:09am
Algernon claimed to be a Phase II clinical trial company.
The reality is Algernon still has not launched a real Phase II clinical trial. It has only conducted Phase II "studies" to study if it wants to run a real Phase II clinical trial. The IPF
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Dec 23, 2021 12:08pm
Bullrun Stocks R BS N Algernon Is The Worst Of The BS!
Period
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Dec 23, 2021 12:05pm
The Market
What is this "market"? total trades on CSE today after 2 hours are 400 shares. Typically, trading is mostly a few day traders playing with themselves and,IMHO, that's the problem -
...more
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Post by
TheBearInTheWoods
on Dec 23, 2021 7:20am
.045 what a fall from .58
Most likely because the market realized AGN doesn't have any patents and you can buy the drug over the counter in Japan. For the price of two shares!
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Dec 21, 2021 9:45pm
RE:RE:RE:RE:RE:RE:RE:Wednesday Trading
Yeah, it's critical Algernon uplist ASAP. Other than CSE-OTC being somewhat incompetent in understanding biotech valuatrions, the glaringv internal problem with algernon is it's timelines to
...more
(334)
•••
Goldhog
X
View Profile
View Bullboard History
Comment by
Goldhog
on Dec 21, 2021 3:29pm
RE:RE:RE:RE:RE:RE:Wednesday Trading
Good one. I do think we uplist and score large from here
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Dec 21, 2021 12:49pm
RE:RE:RE:RE:RE:Wednesday Trading
Pay attention. One is murder be killed). The other is natural cause (DIE). My response was in the context of what you wrote. Meaning, Algernon will continue to experience a slow death by not uplifting
...more
(1121)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Dec 21, 2021 11:20am
RE:Q&A: CEO's Statement(s) Regarding Chronic Cough Competition
My apologies, it's what happens when you depend on your aged brain and don't go back and look at the documents. This is the statement I was referring to and it did not include Bellus but did
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Dec 21, 2021 11:10am
RE:RE:RE:RE:Wednesday Trading
At the risk of seeming pedantic, perhaps "uplist or be killed"?
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Dec 20, 2021 7:16pm
RE:RE:RE:Wednesday Trading
It's the story of Algernon's life on the CSE/OTC. UPLIST OR DIE
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Dec 20, 2021 3:05pm
RE:RE:Wednesday Trading
Follow the trades on www.thecse.com (search for AGN) You will see, almost invariably, following positive news from the company or where the outloo is generally positive, that the market price is
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Dec 19, 2021 3:10pm
RE:Q&A: CEO's Statement(s) Regarding Chronic Cough Competition
Correction - In my opinion: As of right now, Bellus Health appears to have the best clinical trial results to beat with a reported 34% reduction in Cough. However, Bellus Health’s drug is
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Meet the Top 5 Best Online Brokerages in Canada
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Star Diamond Corporation Announces Third Quarter 2024 Results
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023